Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study

[1] Liu L(2016)Cancer in Europe: death sentence or life sentence? Eur J Cancer 65 150-155

[2] O’Donnell P(2018)Long-term quality of life profile in oncology: a comparison between cancer survivors and the general population Support Care Cancer 26 651-656

[3] Sullivan R(2018)Return to work in European Cancer survivors: a systematic review Support Care Cancer 26 2983-2994

[4] Katalinic A(2019)Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors J Oncol 2019 5269062-1674

[5] Moser L(2018)Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma J Clin Oncol 36 1668-54

[6] de Boer A(2016)Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma Eur J Cancer 67 46-1302

[7] Annunziata MA(2019)Time to study metastatic-cancer survivorship N Engl J Med 380 1300-570

[8] Muzzatti B(2019)An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors Supportive Care in Cancer 28 561-198

[9] Flaiban C(2016)A systematic review examining factors influencing health related quality of life among melanoma cancer survivors Eur J Cancer 69 189-17

[10] Gipponi K(2015)Depression, anxiety and quality of life in long-term survivors of malignant melanoma: a register-based cohort study PLoS One 10 1-1852

[1] Liu L(2016)Cancer in Europe: death sentence or life sentence? Eur J Cancer 65 150-155

[2] O’Donnell P(2018)Long-term quality of life profile in oncology: a comparison between cancer survivors and the general population Support Care Cancer 26 651-656

[3] Sullivan R(2018)Return to work in European Cancer survivors: a systematic review Support Care Cancer 26 2983-2994

[4] Katalinic A(2019)Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors J Oncol 2019 5269062-1674

[5] Moser L(2018)Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma J Clin Oncol 36 1668-54

[6] de Boer A(2016)Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma Eur J Cancer 67 46-1302

[7] Annunziata MA(2019)Time to study metastatic-cancer survivorship N Engl J Med 380 1300-570

[8] Muzzatti B(2019)An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors Supportive Care in Cancer 28 561-198

[9] Flaiban C(2016)A systematic review examining factors influencing health related quality of life among melanoma cancer survivors Eur J Cancer 69 189-17

[10] Gipponi K(2015)Depression, anxiety and quality of life in long-term survivors of malignant melanoma: a register-based cohort study PLoS One 10 1-1852